Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck moves into mRNA space with Moderna alliance

This article was originally published in Scrip

Executive Summary

Moderna Therapeutics, the subject of the largest ever biotech private equity fundraising of $450m earlier this month (, 6 January 2015), has signed a license and collaboration agreement with Merck & Co for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).

You may also be interested in...

Moderna Prepares For mRNA Drug R&D Blitz With $474m In New Equity

Moderna Therapeutics LLC will go public someday, CEO Stephane Bancel says, but not until the company has human proof-of-concept data for multiple messenger RNA (mRNA) therapeutics – a milestone that Moderna expects to reach with its $474m in new equity financing.

Merck Bets Moderna's Cancer Vaccines Can Prime Patients For Immunotherapy

The companies will work together to develop personalized cancer vaccines against several tumor types, including an effort to pair a personalized vaccine with Keytruda.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts